Primaa is a Paris-based medical software company building AI tools that automate and improve cancer diagnostics on digital histology slides. Its flagship Cleo Breast product (CE-IVDR) automatically detects and quantifies key breast-cancer biomarkers, while Cleo Skin, now undergoing CE marking, targets melanoma, squamous cell carcinoma, and basal cell carcinoma. The software reduces processing time, increases diagnostic reliability, and eases workloads for pathologists at institutions such as Institut Curie, AP-HP, and Saint-Joseph Hospital. Early European rollouts are underway at ZAS Laboratory and Liège University Hospital. Primaa is expanding its portfolio with cervical-cancer and prostate-cancer modules being co-developed with clinical partners. Future product plans include predictive AI models that assess disease progression and relapse risk. The company has raised €7 million to date to fund faster European deployment, bolster customer support, and pursue FDA certification for entry into the U.S. market.

Total raised

$10M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2025